For the bottom up part of the LCA, we account for variability in process and usage pattern data by developing parameter ranges.
Although clear efforts aimed at designing advanced PCMs with well-defined nanostructure for optimizing supercapacitive properties are hot research aspects, e.g., carbon nanospheres [13, 14], carbon nanotubes [15, 16], and carbon nanorods [17, 18], their practical applications are significantly limited by the high cost, multi-step processes, and heavily usage of toxic strong oxidants [19].
The objective of the present study is to investigate and compare the perceptions of first and third-year PBL students on self-study and reporting processes and their usage of learning resources.
Four key themes were revealed: utilizing students' learning experiences to design the CNP's teaching plan; a group-based discussion platform as a communication channel is needed; posting teaching content to facilitate student learning process; and, motivation usage factors in ease of use, sustaining use and win (student) – win (preceptor) outcomes.
When you use location based services, we will collect, transmit, maintain, process, and use your location and usage data (including both real time geographic information and information that can be used to approximate location) in order to provide location based and related services, and to enhance your device experience.
In addition, the study provides a finer-grained analysis of associations between Process and Planning AMT usage and various aspects of manufacturing performance.
Hence, we have to identify not only the bottlenecks but also the gaps in skills and competencies to be addressed in further and more advanced applications of model-based approaches to improve the drug development process and therapeutic usage.
Drug disease modeling and simulation (DDM&S) creates a paradigm for enabling an integrated and higher level of understanding of drugs, (diseased)systems characteristics, and their interactions (systems pharmacology) through mathematical/statistical models (pharmacometrics) throughout the entire R&D process and therapeutic usage.
In this survey, we considered the following independent variables: (i) industrial experience with testing process; (ii) knowledge and usage experience with MR-MPS; and (iii) knowledge of TMMi.
Our proposed framework could help unify perspectives and shared understanding in the same way that the four phases of drug development allow a clearly understood benchmarking process for approval and usage of new pharmaceuticals.
